STSA - Satsuma Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Satsuma Pharmaceuticals's activity chart (see below) currently has 18 price targets and 20 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 53.33% with an average time for these price targets to be met of 92.67 days.

Most recent stock forecast was given by OREN LIVNAT from HC WAINWRIGHT on 18-Apr-2023. First documented stock forecast 08-Oct-2019.

Best performing analysts who are covering STSA - Satsuma Pharmaceuticals:

Marc Goodman Evan Seigerman Vamil Divan Oren Livnat Stephen Kim

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 21-Sep-2022

$3

3 years 5 months 13 days ago
(18-Apr-2023)

0/5 (0%)

$2.29 (322.54%)

Buy

$14

3 years 10 months 14 days ago
(16-Nov-2022)

0/1 (0%)

$8.01 (133.72%)

Buy Since 15-Nov-2022

$1

$-0.1 (-9.09%)

3 years 10 months 16 days ago
(15-Nov-2022)

2/2 (100%)

$0.37 (58.73%)

62

Buy Since 16-Mar-2022

$15

4 years 4 months 18 days ago
(13-May-2022)

2/5 (40%)

$11.22 (296.83%)

192

Sell Since 11-Nov-2020

$6.5

$5.4 (490.91%)

$3.5

5 years 6 months 29 days ago
(02-Mar-2021)

4/4 (100%)

$0.25 (4.00%)

163

Show more analysts

Please expand the browser size to see the chart

What is STSA (Satsuma Pharmaceuticals) average time for price targets to be met?

On average it took 93 days for the stock forecasts to be reached, with an average price target met ratio of 53.33%.

Which analyst most recently updated their price target on STSA (Satsuma Pharmaceuticals)?

Oren Livnat

Which analyst has the most public recommendations on STSA (Satsuma Pharmaceuticals)?

Oren Livnat works at HC WAINWRIGHT and has 4 price targets and 4 ratings on STSA

Which analyst is the currently most bullish on STSA (Satsuma Pharmaceuticals)?

Evan Seigerman with the highest potential upside of $5.4

Which analyst is the currently most reserved on STSA (Satsuma Pharmaceuticals)?

Marc Goodman with the lowest potential downside of -$0.1
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?